Bruker Daltonics Appoints Dr. Michael Schubert as Vice President for Research and Development.To download high-resolution, print-ready JPEG JPEG in full Joint Photographic Experts Group Standard computer file format for storing graphic images in a compressed form for general use. JPEG images are compressed using a mathematical algorithm. images, click on the thumbnail image above. WARNING: these images are very large (800K+) Click here for caption Business Editors/Health/Medical Writers Pittcon 2004 MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4593076 BILLERICA, Mass.--(BUSINESS WIRE)--March 15, 2004 Bruker Daltonics Inc., an operating company operating company A business that engages in transactions with outsiders. of Bruker BioSciences Corporation Bruker Biosciences Corporation is a Massachusetts-based company formed in 2003 which develops and manufactures scientific instrumentation for academic research and industrial use. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : BRKR BRKR Breaker ), announces that Dr. Michael Schubert has been appointed as Vice President for Research and Development. Bruker Daltonics' business has more than tripled in the past 5 years, based on innovative, high-quality products, and a strong commitment to customer service and support. Dr. Schubert will be responsible for the management of the Company's research and development activities worldwide, including R&D activities in the United States, Germany, Switzerland and Japan. In 1992, Michael Schubert received his doctorate from the University of Hamburg As of 2006, the University of Hamburg supports 6 Collaborative Research Centres (Sonderforschungsbereiche, SFB), 6 Research Groups, 7 Research Training Groups (all funded by the DFG), 2 Max Planck Inter-national Research Schools, 13 Young Scientist Groups (Emmy-Noether-Programme, BMBF, in physics. From 1991 to 2000, he was Project Manager in the Bruker Daltonics ion trap program. In 2000, he became responsible for the Company's R&D activities in Bremen, Germany, and since August 2002, Michael has also served as Managing Director of Bruker Daltonik GmbH, located in Bremen and Leipzig, Germany. Frank Laukien, Ph.D., President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Bruker Daltonics, stated: "We are very pleased to have Michael assume this new global R&D position to address the present and future needs of our pharmaceutical, biotech, diagnostics and other life-science customers, as well as our security and defense customers. Michael will drive our development of innovative applications-driven solutions and robust easy-to-use systems for automated routine analysis. He understands our technology base and markets very well, and brings a wealth of experience in managing internal R&D and strategic collaborations." "I am looking forward to leading our global R&D efforts at such an exciting time in the growth of life-science applications of mass spectrometry mass spectrometry or mass spectroscopy Analytic technique by which chemical substances are identified by sorting gaseous ions by mass using electric and magnetic fields. ," commented Dr. Michael Schubert. "Driving sample preparation, consumables, instrument and bioinformatics development for comprehensive applications-oriented solutions offers many great opportunities. We will use our resources and strategic partnerships to offer systems and solutions for expression proteomics, clinical proteomics and metabonomics applied to drug discovery and development, as well as to clinical and academic research. A special R&D focus will also be on advanced chemical and biological detection systems for homeland security and defense." ABOUT BRUKER BIOSCIENCES Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker AXS Inc. and Bruker Daltonics Inc. Bruker AXS is a leading developer and provider of life science and advanced materials research tools based on X-ray technology. Bruker Daltonics is a leading developer and provider of innovative life science tools based on mass spectrometry. For more information, please visit www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's reorganization strategies, integration risks, failure of conditions, technological approaches, product development, market acceptance, cost and pricing of the Company's products, changes in governmental regulations, capital spending capital spending Spending for long-term assets such as factories, equipment, machinery, and buildings that permits the production of more goods and services in future years. and government funding policies, FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our respective annual reports on Form 10-K for the year ended December 31, 2002, our most recent quarterly reports on Form 10-Q, our current reports on Form 8-K and the joint proxy statement/prospectus filed in connection with the merger. We disclaim any intent or obligation to update these forward-looking statements. MULTIMEDIA AVAILABLE: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=4593076 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion